clinical trials

The US Food and Drug Administration has just approved a game-changing pill that can lower LDL cholesterol by around 60%. It's the first protein inhibitor to be made into a daily oral pill, doing away with the need for injections.

The US Food and Drug Administration has issued its first comprehensive guide on how psychedelic drugs should be studied in trials, signalling a shift toward recognizing the potential of these therapeutics and what's needed to see them approved.

A new treatment has shown promise in reducing migraine pain with targeted ear acupuncture, opening the door to therapy that could be used as a complementary procedure alongside existing medication prescribed to those with the debilitating condition.

A comprehensive global review has found that mRNA vaccines are not just highly effective at fighting infectious diseases but are also very safe. And that they have the potential to revolutionize how we treat influenza, RSV and many cancers.

A novel three-in-one medication has been put to the test in a trial of 212 heart failure patients, in an effort to find an easier and more effective way to treat the condition. The findings were just what the scientists had hoped to see.

A once-a-day oral GLP-1 pill known as CX11 has met its dosage and efficacy goals in a trial on US patients and will now advance to its first North American Phase 3 trial. It's already cleared this final hurdle in China where it awaits approval.

A landmark study is due to start in the coming months, and if successful it could ultimately revive our immune system in older age and even treat chronic illnesses like autoimmune disease. The Phase 1 trial is aiming to rejuvenate senescent T cells.

Definium Therapeutics has announced the strong Phase 3 results of its single-dosed lysergide drug DT120 in treating adults with major depressive disorder. It met its main goal and all key secondary efficacy endpoints in the first trial of its kind.

We may be on the cusp of understanding whether we can turn back time for our cells to stave off age-related disease, with the first human receiving experimental gene therapy as part of a landmark trial.

We might be on the verge of a critical breakthrough treatment for pattern hair loss, with a novel slow-release oral drug meeting its significant endpoints in a Phase II/III trial of 519 patients. The next results are due later this year.

In a breakthrough study, researchers have found that the world's most common type of arthritis – osteoarthritis (OA) – actually has a single core driver with clean-cut molecular pathways. It paves the way for much better treatment.

Scientists are confident they've got the first effective Lyme disease vaccine, but the final hurdle will be FDA approval – which the drug-makers are seeking despite unexpected statistical issues. It remains to be seen if this will derail their goals.